NEW YORK (GenomeWeb) – Vermillion and Quest Diagnostics have agreed to extend and amend their commercialization and services agreement for Vermillion's OVA1 ovarian cancer test.

In a March 7, 2017 filing with the US Securities and Exchange Commission, Vermillion said it had amended the agreement to extend the initial term from March 11, 2017 to March 11, 2018 while also providing an option for an additional one-year renewal.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.